Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated Shs Cert Deposito Arg Repr 0.00990099 Shs's next confirmed earnings release is scheduled for November 2, 2026.

As of June 30, 2026, Vertex Pharmaceuticals Incorporated Shs Cert Deposito Arg Repr 0.00990099 Shs has 23.95B shares outstanding.

As of June 30, 2026, Vertex Pharmaceuticals Incorporated Shs Cert Deposito Arg Repr 0.00990099 Shs maintains a current ratio of 3.19, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.77, indicating elevated leverage, while an interest coverage ratio of 757.45 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Vertex Pharmaceuticals Incorporated Shs Cert Deposito Arg Repr 0.00990099 Shs posted a return on equity (ROE) of 23.54, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 19.50 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 17.12, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 21.55, useful for judging operating efficiency across full business cycles. The company generates approximately 1.99M in revenue per employee across its workforce of 6,325.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.08 indicates how many times Vertex Pharmaceuticals Incorporated Shs Cert Deposito Arg Repr 0.00990099 Shs sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Vertex Pharmaceuticals Incorporated Shs Cert Deposito Arg Repr 0.00990099 Shs recorded 869.30M in income tax expense. That works out to an effective tax rate of 16.48, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 5.27B, leaving 4.41B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Vertex Pharmaceuticals Incorporated Shs Cert Deposito Arg Repr 0.00990099 Shs generated 12.59B in revenue and converted that into 4.41B in net income, yielding earnings per share of 0.18. EBITDA reached 5.00B, while operating income came in at 4.78B.

As of June 30, 2026, Vertex Pharmaceuticals Incorporated Shs Cert Deposito Arg Repr 0.00990099 Shs holds 7.85B in cash and equivalents against 1.98B in total debt, resulting in a net debt position of -6.14B. Total book value stands at 20.25B, with working capital of 8.61B providing operational flexibility.

Vertex Pharmaceuticals Incorporated Shs Cert Deposito Arg Repr 0.00990099 Shs produced 4.29B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -496.80M in capital expenditures, free cash flow totaled 3.80B - equivalent to 0.16 per share.

Over the twelve months ended June 30, 2026, Vertex Pharmaceuticals Incorporated Shs Cert Deposito Arg Repr 0.00990099 Shs posted a gross margin of 86.00, reflecting its pricing power and cost economics. The operating margin of 37.95 and net profit margin of 35.00 provide insight into operational efficiency.